RPL17 and neoplasm: First immune checkpoint-related keywords (e.g., PD-1/PD-L1 CTLA-4) highlight tumor immune evasion mechanisms as seen in Peng et al. (35) who found that nivolumab upregulates PD-L1 via the NF-κB pathway to create an immunosuppressive microenvironment.